Mode
Text Size
Log in / Sign up

Combined exercise is most effective for cancer-related fatigue and lean mass in breast cancerCombined exercise helps breast cancer patients manage fatigue and strength

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider combined exercise for fatigue and lean mass, and resistance exercise for muscle strength in breast cancer patients.

This systematic review and dose-response network meta-analysis synthesized data from 64 trials to evaluate the impact of different exercise modalities on women with breast cancer during and following primary treatment. The study included a total population of 5156 women. The primary outcomes analyzed were cancer-related fatigue, lean mass, physical function, and muscle strength. The interventions evaluated were aerobic exercise (AE), resistance exercise (RE), and combined (COMB) exercise programs.

Regarding the primary outcome of cancer-related fatigue, the analysis identified COMB as the most effective modality. The results indicated that the smallest effective dose of COMB associated with significant changes was 18 METs.min/week, which showed an effect size of SMD 0.23 (95% CI 0.18 to 0.28). The study further noted that fatigue benefits plateaued at approximately 1428 METs.min/week for COMB, where the effect size was SMD 0.58 (95% CI 0.46 to 0.69).

For the outcome of lean mass, COMB was again identified as the most effective modality. The smallest effective dose of COMB for lean mass was 11 METs.min/week, resulting in an effect size of SMD 0.30 (95% CI 0.22 to 0.38). Notably, no plateau was observed across the evaluated dose range for lean mass in the COMB group.

In contrast, for physical function and muscle strength, resistance exercise (RE) was identified as the most effective modality. For physical function, a dose of approximately 7-8 METs.min/week produced significant improvements with an effect size of SMD 0.23 (95% CI 0.15 to 0.30). For muscle strength, a dose of approximately 7-8 METs.min/week also produced significant improvements with an effect size of SMD 0.24 (95% CI 0.20 to 0.29). Similar to the lean mass findings, no plateau was observed across the evaluated dose range for muscle strength in the RE group.

Safety and tolerability data, including specific adverse event rates or discontinuation rates, were not reported in the included data. The study notes that the results are based on a synthesis of 64 trials, and the association between exercise and outcomes was established via network meta-analysis of randomized controlled trials.

Methodological limitations were not specifically detailed. However, the study highlights that the results are a synthesis of multiple trials, which may introduce variability. The clinical implications suggest that significant benefits for the assessed outcomes can be achieved with exercise doses as low as 10-40 min/week. This suggests that even relatively low-volume interventions may be clinically relevant for patients with breast cancer.

Several questions remain regarding the optimal long-term maintenance of these gains and the specific preferences of patients regarding exercise modalities. While the meta-analysis provides a clear hierarchy of effectiveness for different outcomes, the specific nuances of individual patient tolerance and the most effective integration of AE and RE into standard care protocols require further investigation.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in the management of physical symptoms and functional status in breast cancer patients. While previous evidence has focused on systemic treatments like sacituzumab govitecan for metastatic disease and radiation techniques to reduce heart and LAD doses, this review provides specific evidence for non-pharmacological interventions to manage cancer-related fatigue and muscle mass.

Living with breast cancer often comes with physical challenges that go beyond the primary treatment. Many women experience significant fatigue, which can make daily tasks difficult and impact their quality of life. Additionally, maintaining muscle strength and physical function is important for staying active and independent during and after cancer treatment. This research looks at how different types of exercise might help address these specific physical concerns.

To understand the best approach, researchers conducted a systematic review and network meta-analysis. They looked at data from 64 different trials involving over 5,000 women with breast cancer. The researchers compared three main types of exercise: aerobic exercise, which focuses on heart health; resistance exercise, which focuses on muscle strength; and a combination of both types of exercise.

The findings showed that combining aerobic and resistance exercise was the most effective way to reduce cancer-related fatigue. The study found that even relatively small amounts of combined exercise were enough to see a difference. For muscle strength and physical function, resistance exercise was found to be highly effective. The data suggested that patients could see improvements in their physical abilities with just a small amount of consistent effort. Specifically, the study noted that benefits for these physical goals could be achieved with exercise doses as low as 10 to 40 minutes per week.

While these results are encouraging, it is important to remember that this was a meta-analysis, which means it is a summary of many different studies rather than one single new trial. Because it is a summary of existing data, the results reflect a general trend rather than a specific guarantee for every individual. There were no reports of safety concerns or adverse events in the data reviewed.

For patients today, this means that exercise is a practical tool for managing the physical side effects of breast cancer. Instead of needing hours of intense training, the data suggests that a mix of cardio and strength training can be effective even in small doses. Patients should speak with their healthcare team or a physical therapist to create a personalized exercise plan that fits their specific energy levels and goals.

What this means for you:
Combining aerobic and resistance exercise may help breast cancer patients improve strength and reduce fatigue.

Study Details

Study typeSystematic review
Sample sizen = 5,156
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
OBJECTIVE: To systematically review and investigate the dose-response (DR) relationship of aerobic exercise (AE), resistance exercise (RE) and combined (COMB) exercise programmes on cancer-related fatigue, lean mass, physical function and muscle strength in women with breast cancer during and following primary treatment. DESIGN: Systematic review with DR network meta-analysis (DR-NMA; CRD42023491118). DATA SOURCES: CINAHL, Embase, LILACS, PubMed, SciELO, SPORTDiscus and Web of Science were searched from inception to 10 January 2024, with an updated search in April 2025. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials evaluating COMB, RE or AE in women with breast cancer on the four specified outcomes. RESULTS: 64 trials (n=5156) were included. COMB was the most effective modality for improving fatigue and lean mass, and RE was the most effective for improving physical function and muscle strength. The smallest effective doses of COMB associated with significant changes in fatigue (standardised mean differences (SMD) 0.23 (95% CI 0.18 to 0.28)) and lean mass (SMD 0.30 (95% CI 0.22 to 0.38)) were 18 and 11 metabolic equivalents per week (METs.min/week), respectively. For RE, about 7-8 METs.min/week produced significant improvements in physical function (SMD 0.23 (95% CI 0.15 to 0.30)) and strength (SMD 0.24 (95% CI 0.20 to 0.29)). Fatigue benefits (SMD 0.58 (95% CI 0.46 to 0.69)) plateaued at ~1428 METs.min/week for COMB, whereas no plateau was observed for lean mass or strength across the evaluated dose range, with effects increasing throughout the available dose range. CONCLUSIONS: COMB and RE were the most effective interventions across outcomes in women with breast cancer. Benefits for the outcomes assessed in this systematic review with DR-NMA were achieved with exercise doses as low as 10-40 min/week. PROSPERO REGISTRATION NUMBER: CRD42023491118.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.